Who is sponsoring NCT03140384?

NCT03140384 is sponsored by Centre Hospitalier Universitaire, Amiens.

What condition does NCT03140384 study?

NCT03140384 studies Misoprostol, Drug-induced Abortion.

Is NCT03140384 still recruiting?

NCT03140384 is currently withdrawn. Last updated 17 April 2018.

Last reviewed 2018-04-17 · How we verify

NCT03140384: Misoprostol

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Compare the Different Routes of Administration of Misoprostol During Medicinal Abortion Between 7 and 9 Weeks of Amenorrhoea (SA)

Withdrawn Phase 3 Last updated 17 April 2018

What this trial tests

Phase 3 trial testing Assess the efficacy and side effects of Misoprostol according to the route of administration in Misoprostol. Withdrawn.

Timeline

20 August 2017

Primary endpoint
20 July 2019

20 July 2019

Quick facts

Lead sponsor	Centre Hospitalier Universitaire, Amiens
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	20 August 2017
Primary completion	20 July 2019
Estimated completion	20 July 2019
Sites	1 location across France

Drugs / interventions tested

Assess the efficacy and side effects of Misoprostol according to the route of administration — full drug profile →

Conditions studied

Misoprostol — all drugs for Misoprostol →
Drug-induced Abortion — all drugs for Drug-induced Abortion →

Sponsor

Centre Hospitalier Universitaire, Amiens

Who can join

18 and older, female only, with Misoprostol or Drug-induced Abortion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In France, drug-induced abortion is allowed up to 9SA, after which the surgical route is preferred. Mifepristone 600mg is used 36-48 hours before the introduction of Misoprostol. This is recommended orally at a dose of 400 μg. There are currently several studies on the subject, including a meta-analysis of the 2011 Cochrane Database, but doses, routes of administration and gestational age differ in all studies. Currently, HAS recommends the vaginal route at the dose of 800μg for stopped pregnancies. It is therefore necessary to compare the different routes of administration of Misoprostol at the same dose to allow to change our French recommendations on the medicinal abortion and perhaps also to recommend the vaginal route in this indication.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Medical methods for first trimester abortion.
Zhang J, Zhou K, Shan D, Luo X. · · 2022 · cited 19× · PMID 35608608 · DOI 10.1002/14651858.cd002855.pub5

Verify or expand the search:

Other recruiting trials for Misoprostol

Currently open trials in the same condition.

NCT06946914 — Misoprostol Before Caesarean Section · Phase 4 · recruiting

Other Centre Hospitalier Universitaire, Amiens trials

Trials by the same sponsor.

NCT07354568 — Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock · recruiting
NCT07071662 — Induction of Labor in Breech Presentation · completed
NCT06909487 — Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respec · completed
NCT07037719 — Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE) · recruiting
NCT06996145 — Study of the Isometry of the Anterior Cruciate Ligament From the Center of the Native MRI Insertion Reported on Dynamic · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03140384 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire, Amiens
Last refreshed: 17 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03140384.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing